Tokyo, April 13 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061237) titled 'A two-center prospective observational study of treatment continuity with PICC versus subcutaneous route in hospitalized cancer patients receiving palliative care' on April 13.

Study Type: Observational

Primary Sponsor: Institute - Osaka Rosai Hospital

Condition: Condition - Cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To compare 14-day treatment continuity in real-world practice between peripherally inserted central catheter (PICC) and subcutaneous route (SC) selected as the main route of administration in hospitalized cancer patients who required an additional route because peripheral venous access was difficult or expected to become difficult. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Cancer patients aged 18 years or older receiving palliative care. Patients judged clinically to have difficulty in securing peripheral venous access, or expected to have such difficulty in the near future, and requiring continuation of injectable treatment. Patients for whom either PICC or the subcutaneous route (SC) is considered a clinically appropriate option, and whose attending physician selected one of these routes (initiation of SC or PICC order/insertion). The presence or absence of an implanted port is not restricted; however, only patients in whom the attending physician judged that the port alone was insufficient to continue the main injectable treatment of interest, or that an additional route was clinically necessary, and who were newly selected for PICC or SC, are eligible. Key exclusion criteria - Patients in whom stable injectable treatment can be continued via peripheral venous access and for whom PICC or SC is not clinically considered. Patients with a PICC already inserted by another department or service and already being continuously used as the main route for injectable treatment at the time of study allocation. Patients with an absolute contraindication to PICC insertion, such as obvious infection at the planned insertion site, known deep vein thrombosis of the intended upper extremity or severe venous obstruction, uncontrolled major bleeding risk, or explicit patient refusal. Patients who expressed refusal to participate in the study through the opt-out process. Target Size - 900

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 02 Month 04 Day Anticipated trial start date - 2026 Year 06 Month 01 Day Last follow-up date - 2029 Year 05 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070070

Disclaimer: Curated by HT Syndication.